Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
This is a multicenter, open-label, single arm phase II study to evaluate the efficacy and safety of Infigratinib in patients with locally advanced or metastatic GC or GEJ patient with FGFR2 gene amplification, who have failed at least 2 lines of previous standard systemic treatment .
Gastric Cancer|Gastroesophageal Junction Adenocarcinoma
DRUG: Infigratinib
Objective response rate (ORR), ORR: the proportion of patients with confirmed complete response (CR) or partial response (PR), assessed by the independent review committee (IRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1., Week9/17/25/33 and every 12 weeks after (up to 2 years)|Duration of response (DoR), DoR: the duration from the first evaluation as CR or PR to the first evaluation as progressive disease (PD) or death of any cause, per RECIST v1.1 assessed by investigator (INV) and IRC., Week9/17/25/33 and every 12 weeks after (up to 2 years)|Disease control rate (DCR), DCR: the proportion of patients whose overall response is confirmed to be CR or PR or stable disease (SD) per RECIST v1.1, assessed by INV and IRC., Week9/17/25/33 and every 12 weeks after (up to 2 years)|Investigator evaluated ORR, the proportion of patients with confirmed CR or PR assessed by INV according to RECIST v1.1, Week9/17/25/33 and every 12 weeks after (up to 2 years)|Progression-free survival (PFS), the duration from the first date of treatment to the date of progression or death due to any cause, assessed by INV and IRC, Week9/17/25/33 and every 12 weeks after (up to 2 years)|Overall survival (OS), from the first date of Infigratinib treatment until date of death., from the first date of Infigratinib treatment until date of death.
This is a multicenter, open-label, single arm phase II study to evaluate the efficacy and safety of Infigratinib in patients with locally advanced or metastatic GC or GEJ patient with FGFR2 gene amplification, who have failed at least 2 lines of previous standard systemic treatment .